CTEXLI Drug Patent Profile
Which patents cover Ctexli, and what generic alternatives are available?
Ctexli is a drug marketed by Mirum and is included in one NDA.
The generic ingredient in CTEXLI is chenodiol. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the chenodiol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ctexli
A generic version of CTEXLI was approved as chenodiol by LGM PHARMA on October 22nd, 2009.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CTEXLI?
- What are the global sales for CTEXLI?
- What is Average Wholesale Price for CTEXLI?
Summary for CTEXLI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 4,533 |
| What excipients (inactive ingredients) are in CTEXLI? | CTEXLI excipients list |
| DailyMed Link: | CTEXLI at DailyMed |
Pharmacology for CTEXLI
| Drug Class | Bile Acid |
US Patents and Regulatory Information for CTEXLI
CTEXLI is protected by zero US patents and two FDA Regulatory Exclusivities.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirum | CTEXLI | chenodiol | TABLET;ORAL | 219488-001 | Feb 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Mirum | CTEXLI | chenodiol | TABLET;ORAL | 219488-001 | Feb 21, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
